Source:http://linkedlifedata.com/resource/pubmed/id/15808403
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-4-5
|
| pubmed:abstractText |
NAT2 (arylamine N-acetyltransferase 2) polymorphism, being a key determinant of individual variations in acetylation capacity, is suspected to modify the risk of carcinogen-related malignancies. As tobacco smoke and other inhaled hazards contain a variety of NAT2 substrates, the relationship between NAT2 phenotype and lung cancer (LC) risk has been a subject of intensive research, however different case-control studies produced controversial data. In the present report, we employed a novel 'comparison of extremes' approach, i.e. we compared the distribution of NAT2 genotypes in lung cancer patients (LC, n=178) not only to the population controls (healthy donors (HD), n=364), but also to the subjects with a putative cancer-resistant constitution (elderly tumor-free smokers and non-smokers (ED), n=351). Frequencies of homozygous rapid, heterozygous rapid and slow acetylators were 6, 39 and 56% in LC, 8, 32 and 60% in HD, and 6, 35 and 59% in ED, respectively. Comparison of the NAT2 genotype frequencies between affected and non-affected individuals did not reveal any statistical deviations, irrespectively of smoking history, gender, age, or histological type of LC. Adjusted odds ratio for rapid vs. slow acetylators was 1.12 (95% confidence intervals (CI): 0.73-1.74) comparing LC vs. HD, and 1.10 (95% CI: 0.74-1.62) comparing LC vs. ED. Similar distribution of NAT2 acetylator genotypes both in tumor-prone and in tumor-resistant groups suggests that, despite the presence of NAT2 carcinogenic substrates in tobacco smoke, NAT2 polymorphism does not play a noticeable role in lung cancer susceptibility.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0304-3835
|
| pubmed:author |
pubmed-author:BelogubovaEvgeniya VEV,
pubmed-author:CascorbiIngolfI,
pubmed-author:HansonKaido PKP,
pubmed-author:HirvonenAriA,
pubmed-author:ImyanitovEvgeny NEN,
pubmed-author:KarpovaMaria BMB,
pubmed-author:KuliginaEkatherina ShESh,
pubmed-author:MosyaginIgorI,
pubmed-author:PopowskiKatrinK,
pubmed-author:ShutkinVladimir AVA,
pubmed-author:TogoAlexandr VAV,
pubmed-author:UlibinaJulia MJM
|
| pubmed:issnType |
Print
|
| pubmed:day |
28
|
| pubmed:volume |
221
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
177-83
|
| pubmed:dateRevised |
2010-9-8
|
| pubmed:meshHeading |
pubmed-meshheading:15808403-Acetylation,
pubmed-meshheading:15808403-Adolescent,
pubmed-meshheading:15808403-Adult,
pubmed-meshheading:15808403-Aged,
pubmed-meshheading:15808403-Aged, 80 and over,
pubmed-meshheading:15808403-Arylamine N-Acetyltransferase,
pubmed-meshheading:15808403-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15808403-Carcinoma, Small Cell,
pubmed-meshheading:15808403-Carcinoma, Squamous Cell,
pubmed-meshheading:15808403-Female,
pubmed-meshheading:15808403-Gene Frequency,
pubmed-meshheading:15808403-Genetic Predisposition to Disease,
pubmed-meshheading:15808403-Genotype,
pubmed-meshheading:15808403-Heterozygote,
pubmed-meshheading:15808403-Homozygote,
pubmed-meshheading:15808403-Humans,
pubmed-meshheading:15808403-Lung Neoplasms,
pubmed-meshheading:15808403-Male,
pubmed-meshheading:15808403-Middle Aged,
pubmed-meshheading:15808403-Odds Ratio,
pubmed-meshheading:15808403-Polymorphism, Genetic,
pubmed-meshheading:15808403-Risk Factors,
pubmed-meshheading:15808403-Smoking,
pubmed-meshheading:15808403-Tumor Markers, Biological
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
|
| pubmed:affiliation |
Group of Molecular Diagnostics, N.N. Petrov Institute of Oncology, Pesochny-2, St-Petersburg 197758, Russian Federation.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|